Clinical trials
Musculoskeletal Diseases trials in Switzerland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Recruiting | 4 |
| Terminated | 2 |
| Not yet recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AbbVie | 5 |
| Bern University of Applied Sciences | 2 |
| PTC Therapeutics | 2 |
| Zurich University of Applied Sciences | 2 |
| Amgen | 1 |
| Ente Ospedaliero Cantonale, Bellinzona | 1 |
| European Alliance of Associations in Rheumatology | 1 |
| Huub van Hedel | 1 |
| Insel Gruppe AG, University Hospital Bern | 1 |
| Institut Universitaire Romand de Sante au Travail | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Musculoskeletal Diseases | 26 |
| Joint Diseases | 7 |
| Arthritis | 6 |
| Arthritis, Rheumatoid | 4 |
| Nervous System Diseases | 4 |
| Muscular Diseases | 3 |
| Neck Pain | 3 |
| Neuromuscular Diseases | 3 |
| Genetic Diseases, Inborn | 2 |
| Genetic Diseases, X-Linked | 2 |
Trials
Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.